141 related articles for article (PubMed ID: 22490049)
21. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives.
Riou JF; Helissey P; Grondard L; Giorgi-Renault S
Mol Pharmacol; 1991 Nov; 40(5):699-706. PubMed ID: 1658605
[TBL] [Abstract][Full Text] [Related]
22. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
23. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of heterobimetallic topoisomerase I and II inhibitor complexes: in vitro DNA binding, interaction with 5'-GMP and 5'-TMP and cleavage studies.
Arjmand F; Muddassir M
J Photochem Photobiol B; 2010 Oct; 101(1):37-46. PubMed ID: 20638859
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues.
Woo S; Kang DH; Nam JM; Lee CS; Ha EM; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2010 Sep; 45(9):4221-8. PubMed ID: 20619511
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of inhibitory effects of benzothiazole and 3-amino-benzothiazolium derivatives on DNA topoisomerase II by molecular modeling studies.
Aki-Yalcin E; Ertan-Bolelli T; Taskin-Tok T; Ozturk O; Ataei S; Ozen C; Yildiz I; Yalcin I
SAR QSAR Environ Res; 2014; 25(8):637-49. PubMed ID: 25027467
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.
Sengupta T; Mukherjee M; Das A; Mandal C; Das R; Mukherjee T; Majumder HK
Biochem J; 2005 Sep; 390(Pt 2):419-26. PubMed ID: 15901238
[TBL] [Abstract][Full Text] [Related]
28. Structural and Metal Ion Effects on Human Topoisomerase IIα Inhibition by α-(N)-Heterocyclic Thiosemicarbazones.
Morris WH; Ngo L; Wilson JT; Medawala W; Brown AR; Conner JD; Fabunmi F; Cashman DJ; Lisic EC; Yu T; Deweese JE; Jiang X
Chem Res Toxicol; 2019 Jan; 32(1):90-99. PubMed ID: 30484632
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
30. Some benzoxazoles and benzimidazoles as DNA topoisomerase I and II inhibitors.
Oksuzoglu E; Tekiner-Gulbas B; Alper S; Temiz-Arpaci O; Ertan T; Yildiz I; Diril N; Sener-Aki E; Yalcin I
J Enzyme Inhib Med Chem; 2008 Feb; 23(1):37-42. PubMed ID: 18341251
[TBL] [Abstract][Full Text] [Related]
31. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and enantiopreferential DNA-binding profile of late 3d transition metal R- and S-enantiomeric complexes derived from N,N-bis-(1-benzyl-2-ethoxyethane): Validation of R-enantiomer of copper(II) complex as a human topoisomerase II inhibitor.
Arjmand F; Sharma GC; Muddassir M; Tabassum S
Chirality; 2011 Aug; 23(7):557-67. PubMed ID: 21695735
[TBL] [Abstract][Full Text] [Related]
33. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
35. Molecular Docking Based Analysis to Elucidate the DNA Topoisomerase IIβ as the Potential Target for the Ganoderic Acid; A Natural Therapeutic Agent in Cancer Therapy.
Sharma KK; Singh B; Mujwar S; Bisen PS
Curr Comput Aided Drug Des; 2020; 16(2):176-189. PubMed ID: 31429692
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.
Loza-Mejía MA; Olvera-Vázquez S; Maldonado-Hernández K; Guadarrama-Salgado T; González-Sánchez I; Rodríguez-Hernández F; Solano JD; Rodríguez-Sotres R; Lira-Rocha A
Bioorg Med Chem; 2009 May; 17(9):3266-77. PubMed ID: 19364657
[TBL] [Abstract][Full Text] [Related]
37. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
38. 4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II.
Christodoulou MS; Zarate M; Ricci F; Damia G; Pieraccini S; Dapiaggi F; Sironi M; Lo Presti L; García-Argáez AN; Dalla Via L; Passarella D
Eur J Med Chem; 2016 Aug; 118():79-89. PubMed ID: 27128175
[TBL] [Abstract][Full Text] [Related]
39. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
40. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
